前列腺癌转移与健康差异:一项系统综述
本系统综述检索PubMed、Google Scholar和Science Direct数据库,探讨非洲裔与欧洲裔男性在前列腺癌转移差异中的潜在机制、治疗及生存差异。研究提示上皮-间质转化、炎症和生长激素信号等独特遗传特征与分子机制参与转移差异;非洲裔患者对恩扎卢胺和免疫治疗反应更好,但获取这些药物的机会更少。作者结论认为遗传背景、肿瘤微环境与健康社会决定因素共同影响转移侵袭性和治疗结局,针对差异的诊疗局限需要严谨研究关注。
要点
- 非洲裔男性转移性前列腺癌疾病负担不成比例地高于欧洲裔男性。
- 上皮-间质转化、炎症和生长激素信号等机制参与转移差异。
- 非洲裔患者对恩扎卢胺和免疫治疗反应更好,但药物可及性更低。
核心结论
- 越来越多的证据表明,患者遗传特征、前列腺肿瘤微环境与健康社会决定因素之间存在联系,共同导致转移性疾病侵袭性和治疗结局的差异。
- 作者认为,针对前列腺癌转移差异的当前诊断和治疗应用存在局限,需要严谨的研究关注。
研究设计与样本
- 系统综述,检索PubMed、Google Scholar和Science Direct数据库,纳入原始研究论文和综述文章。
主要发现
- 研究提示独特遗传特征以及上皮-间质转化(EMT)、炎症和生长激素信号等分子机制参与转移性前列腺癌差异。
- 临床研究显示治疗结局存在种族特异性差异,例如非洲裔患者对恩扎卢胺和免疫治疗反应更好,但相较欧洲裔患者获取这些药物的机会更少。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer (PCa), one of the most prevalent malignancies affecting men, significantly contributes to increased mortality rates worldwide. While the causative death is due to advanced metastatic disease, this occurrence disproportionately impacts men of African descent compared to men of European descent. In this review, we describe potential mechanisms underlying PCa metastases disparities and current treatments for metastatic disease among these populations, differences in treatment outcomes, and survival rates, in hopes of highlighting a need to address disparities in PCa metastases. METHODS: We reviewed existing literature using databases such as PubMed, Google Scholar, and Science Direct using the following keywords: "prostate cancer metastases", "metastatic prostate cancer disparity", "metastatic prostate cancer diagnosis and treatment", "prostate cancer genetic differences and mechanisms", "genetic differences and prostate tumor microenvironment", and "men of African descent and access to clinical treatments". The inclusion criteria for literature usage were original research articles and review articles. RESULTS: Studies indicate unique genetic signatures and molecular mechanisms such as Epithelial-Mesenchymal Transition (EMT), inflammation, and growth hormone signaling involved in metastatic PCa disparities. Clinical studies also demonstrate differences in treatment outcomes that are race-specific, for example, patients of African descent have a better response to enzalutamide and immunotherapy yet have less access to these drugs as compared to patients of European descent. CONCLUSIONS: Growing evidence suggests a connection between a patient's genetic profile, the prostate tumor microenvironment, and social determinants of health that contribute to the aggressiveness of metastatic disease and treatment outcomes. With several potential pathways highlighted, the limitations in current diagnostic and therapeutic applications that target disparity in PCa metastases warrant rigorous research attention.
引用
- Liadi Y, Campbell T, Dike P, et al. Prostate cancer metastasis and health disparities: a systematic review. Prostate Cancer Prostatic Dis. 2023. PMID: 37046071. doi:10.1038/s41391-023-00667-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。